Confronto
Enfuvirtid vs. LL-37
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
159519-65-0
597562-32-8
Peso molecolare
4491.88 g/mol
4493.33 g/mol
Emivita
nessun dato
nessun dato
Sequenza
nessun dato
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMeccanismo d'azione
Enfuvirtid
Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
1
4
di cui sull'uomo
1
1
Effetti registrati
2
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Enfuvirtid and LL-37?
- Enfuvirtid is classified as "Ricerca (altro)", while LL-37 is classified as "Ricerca (altro)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Enfuvirtid or LL-37?
- The highest available evidence level is "RCT sull'uomo" for Enfuvirtid and "Studio sull'uomo" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Enfuvirtid and LL-37 in Germany and the United States?
- Germania: Enfuvirtid — Su prescrizione, LL-37 — Solo ricerca. Stati Uniti: Enfuvirtid — Su prescrizione, LL-37 — Solo ricerca. These are factual summaries with source and review date on the individual pages.